Amos de Jong

Class of:

2020

Current affiliation:

Utrecht University

Contact:

a.j.dejong@uu.nl

Motivation:

I am motivated to contribute to reshaping the way clinical trials are conducted, which can benefit patients. During this PhD project, we aim to provide insight in the regulatory aspects of remote decentralized clinical trials (RDCTs), by evaluating regulatory barriers and facilitators to RDCTs in the European Union. RDCTs hold the promise of (amongst others) increasing recruitment and retention rates and improving patient experience.

 

Education and experience:

Education

Master of Science, Biomedical Sciences, VU University, Amsterdam, the Netherlands (2018-2020)

Bachelor of Science, Health and Life Sciences, VU University, Amsterdam, the Netherlands (2015-2018)

 

Experience

2020: MSc Internship, Towards Improved Clinical Trial Monitoring, Diagram B.V., Zwolle, the Netherlands

2019: MSc literature thesis, Lyme disease vaccines: Turbulent Past, Promising Futrue, Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam, the Netherlands

2019: MSc Internship, The use of Salmonella as a vector for TALEs to alter gene expression of host cells, Department of Medical Microbiology, Amsterdam UMC, Amsterdam, the Netherlands

2018: BSc Internship, Evaluating the effect of galunisertib in precision-cut intestinal slices, Department of Pharmaceutical Technology and Biopharmacy, University of Groningen (RUG), Groningen, the Netherlands

 

Title Ph.D. project:

Regulatory Aspects of Remote Decentralized Clinical Trials

 

Team members and other people involved:

Dr. Helga Gardarsdottir, Prof. dr. Anthonius de Boer and dr. Mira Zuidgeest

Publications:

1. Contributed to the following publication: Predictive Value of Precision-Cut Kidney Slices as an Ex Vivo Screening Platform for Therapeutics in Human Renal Fibrosis. Pharmaceutics 2020, 12, 459